Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 676-685

  Moreaux, J ^a,b   Reme, T ^a,b   Leonard, W ^b   Veyrune, J L ^a,b   Requirand, G ^a   Goldschmidt, H ^c,d   Hose, D ^c   Klein, B ^a,b,e  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d Nationales Centrum fur Tumorerkrankungen   (Germany)

^e UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTONE ACETYLATION SCORE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; UPREGULATION;

ACETYLATION; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MULTIPLE MYELOMA; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; TRANSCRIPTOME; UP-REGULATION;

EID: 84883199255     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.392     Document Type: Article

References (70)

1. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy Jr JD, Kuehl WM, Staudt LM (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2): 115-130.
2. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 15(16): 5250-5257.
3. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dumpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29(3): 255-265.
4. Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2(Suppl 1): S4-S11.
5. Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23(26): 6333-6338.
6. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102(7): 2615-2622.
7. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942): 834-840.
8. Cui X, Churchill GA (2003) Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 4(4): 210.
9. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100(1): 194-199.
10. Dimopoulos MA, Sundar J, Yoon SS, Siegel DS, Lonial S, Hajek R, Facon T, Rosiñol L, Blacklock A, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Reece DE, Graef T, Houp J, Sun L, Eid JE, Anderson KC (2011) Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. Blood (118): 368-369; abstract 811; oral presentation.
11. Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH, Lentzsch S (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 7(6): 1494-1505.
12. Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, Wijdenes J, Klein B (2000) Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 14(1): 188-197.
13. Hahn WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl J Med 347(20): 1593-1603.
14. Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, Dean J, Januszewicz H, Johnstone R, Neeson P, Dickinson M, Nichols J, Prince HM (2011) A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 118(24): 6274-6283.
15. Hartl M, Nist A, Khan MI, Valovka T, Bister K (2009) Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1). Proc Natl Acad Sci USA 106(14): 5604-5609.
16. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, Zielinski CC, Drach J, Zochbauer-Muller S (2008) Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 68(1): 44-54.
17. Hideshima T, Anderson KC (2013) Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol 97(3): 324-332.
18. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104(3): 607-618.
19. Hideshima T, Richardson PG, Anderson KC (2011) Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 10(11): 2034-2042.
20. Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Saito Y (2011) Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis. Oncol Rep 26(5): 1057-1062.
21. Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B (2003) A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22(19): 2950-2959.
22. Kahali S, Sarcar B, Chinnaiyan P (2011) The emerging role of histone deacetylases (HDACs) in UPR regulation. Methods Enzymol 490: 159-174.
23. Kahali S, Sarcar B, Prabhu A, Seto E, Chinnaiyan P (2012) Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB J 26(6): 2437-2445.
24. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91(2): 248-251.
25. Kassambara A, Hose D, Moreaux J, Reme T, Torrent J, Rossi JF, Goldschmidt H, Klein B (2012a) Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. PLoS One 7(7): e42161.
26. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B (2012b) Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 97(4): 622-630.
27. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12(2): 131-144.
28. Kelly TK, De Carvalho DD, Jones PA (2010) Epigenetic modifications as therapeutic targets. Nat Biotechnol 28(10): 1069-1078.
29. Khan SB, Maududi T, Barton K, Ayers J, Alkan S (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125(2): 156-161.
30. Kondo Y (2009) Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 50(4): 455-463.
31. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32): 5459-5468.
32. Larocque D, Galarneau A, Liu HN, Scott M, Almazan G, Richard S (2005) Protection of p27(Kip1) mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation. Nat Neurosci 8(1): 27-33.
33. Lavelle D, Chen YH, Hankewych M, DeSimone J (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68(3): 170-178.
34. Mahtouk K, Jourdan M, De Vos J, Hertogh C, Fiol G, Jourdan E, Rossi JF, Klein B (2004) An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 103(5): 1829-1837.
35. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, AkiyamaM,ChauhanD,MunshiN,GuX, BaileyC, JosephM, Libermann TA, Richon VM, Marks PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101(2): 540-545.
36. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101(10): 4055-4062.
37. Moreau P (2012) The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol 49(Suppl 1): S33-S46.
38. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, Goldschmidt H, Jauch A, Reme T, Jourdan M, Amiot M, Pellat-Deceunynck C (2011) A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96(4): 574-582.
39. Moreaux J, Reme T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D, Klein B (2012) Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol Cancer Ther 11(12): 2685-2692.
40. Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12(5): 335-348.
41. Neri P, Bahlis NJ, Lonial S (2012) Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs 21(5): 733-747.
42. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Viscomi C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P (2008) In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 143(4): 520-531.
43. Niesen MI, Blanck G (2009) Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 32(3): 480-482.
44. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA (2011) Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117(2): 336-342.
45. Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S, Catarini M, Alesiani F, Corvatta L, Gentili S, Caraffa P, Boccadoro M, Leoni P, Palumbo A (2012) Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 53(9): 1722-1727.
46. Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, Ha K, Buckley KM, Balusu R, Coothankandaswamy V, Joshi A, Atadja P, Bhalla KN (2010) Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther 9(4): 942-952.
47. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, Rossi JF, Brochier J, Klein B (1998) A gp130 interleukin-6 transducerdependent SCID model of human multiple myeloma. Blood 91(12): 4727-4737.
48. Reme T, Hose D, De Vos J, Vassal A, Poulain PO, Pantesco V, Goldschmidt H, Klein B (2008) A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinform 9: 16.
49. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49(3): 502-507.
50. Richardson PG, Alsina M, Weber DM, Coutre SE, Lonial S, Gasparetto C, Warsi G, Ondovik M, Mukhopadhyay S, Snodgrass S, Schlossman R (2011) Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). Blood (118): abstract 814 (oral presentation).
51. Rio-Machin A, Ferreira BI, Henry T, Gomez-Lopez G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martinez J, Fonseca R, Cigudosa JC (2013) Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia 27(4): 925-931.
52. San-Miguel JF, Hungria VT, Yoon SS, Wikto-Jedrzejczak W, Elghandour A, Siritanaratkul N, Dimopoulos MA, Corradini P, Nakorn TN, Shelekhova T, Günther A, Yong K, Schlossman R, Wroclawska-Swacha M, Weber HJ, Bourquelot P, Hou J, Einsele H, Lee JH, Moreau P, Lonial S, Richardson PG (2011) Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1. Blood (118): abstract 3976.
53. San-Miguel JF, SO, Siegel DS, Sezer O, Siegel DS, Guenther A, Mateos MV, Prosser I, Cavo M, Blade J, Boccadoro M, Bengoudifa BR, Klebsattel M, Bourquelot PM, Anderson KC (2009) A phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. Blood (114): 1481-1482; abstract 3852.
54. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM (2008) IRF4 addiction in multiple myeloma. Nature 454(7201): 226-231.
55. Siegel DS, Dimopoulos MA, Yoon S-S, Laubach JP, Kaufman JL, Goldschmidt H, Reece DE, Leleu X, Durrant S, Offner FC, Cavo M, Nagler A, Jagannath S, Graef T, Houp J, Sun L, Howe J, Wear SM, Anderson KC (2011) Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood (114): abstract 480.
56. Siegel DS, Sezer O, San-Miguel JF, Mateos MV, Prosser I, Cavo M, Jalaluddin M, Hazel K, Bourquelot PM, Anderson KC (2008) A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. Blood (112): abstract 2781.
57. Skopelitou A, Hadjiyannakis M, Tsenga A, Theocharis S, Alexopoulou V, Kittas C, Agnantis N (1993) Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases. Anticancer Res 13(4): 1091-1095.
58. Tanguy Le Carrour SA, Tondeur Sylvie, Lhermitte Ludovic, Lamb Ned, Reme Thierry, Pantesco Veronique, Hamamah Samir, Klein Bernard, De Vos John (2010) Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data. Open Bioinform J 4: 5-10.
59. Tarte K, Zhang XG, Legouffe E, Hertog C, Mehtali M, Rossi JF, Klein B (1999) Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J Immunol 163(1): 514-524.
60. Totzke G, Essmann F, Pohlmann S, Lindenblatt C, Janicke RU, Schulze-Osthoff K (2006) A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding. J Biol Chem 281(18): 12645-12654.
61. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8): 789-799.
62. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S (2012) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 53(9): 1820-1823.
63. Wu Z, Zhang X, Yang J, Wu G, Zhang Y, Yuan Y, Jin C, Chang Z, Wang J, Yang X, He F (2009) Nuclear protein IkappaB-zeta inhibits the activity of STAT3. Biochem Biophys Res Commun 387(2): 348-352.
64. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, Chen L, Barlogie B, Shaughnessy Jr JD, Zhan F (2008) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112(10): 4235-4246.
65. Yamazaki S, Muta T, Takeshige K (2001) A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. J Biol Chem 276(29): 27657-27662.
66. Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L, Bai L, Huang B, Shen L, Feng Y, Yao L, Lu Z (2010) RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology 138(1): 231-240, e1-5.
67. Yang G, Lu X, Wang L, Bian Y, Fu H, Wei M, Pu J, Jin L, Yao L, Lu Z (2011) E2F1 and RNA binding protein QKI comprise a negative feedback in the cell cycle regulation. Cell Cycle 10(16): 2703-2713.
68. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265(28): 17174-17179.
69. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy Jr JD (2006) The molecular classification of multiple myeloma. Blood 108(6): 2020-2028.
70. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B (1994) Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83(12): 3654-3663.